Morphology of experimentally induced tumors of the sympathetic nervous system in rats

Бениашвили, Д Ш; Anisimov, Vladimir N.

doi:10.1016/j.etp.2004.05.002

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В процессе индукции ангиогенеза в опухоли происходят как рост новых сосудов, так и их регрессия. Это продемонстрировано на ряде экспериментальных моделей перевиваемых опухолей при исследовании возникновения в опухолевой ткани сосудистой сети [5]. При этом оказалось, что представления о том, что большинство опухолей и метастазов возникает как лишенная сосудов масса клеток и лишь позднее благодаря индукции ангиогенеза в ней формируется поддерживающая развитие опухоли сосудистая сеть, не вполне справедливы.…”

Section: рецепторы Vegfunclassified

Molecular Aspects of Angiogenesis in Brain Glioblastomas

Byvaltsev¹,

Степанов²,

Belykh³

et al. 2017

Problems in oncology

View full text Add to dashboard Cite

It is known that angiogenesis plays a critical role in the growth and progression of brain gliomas. Inducing factor in neoangiogenesis are changes primarily occur within the intra-tumoral events: changing the structure of the microvasculature of tumor tissue, increased hypoxia adaptation of tumor cells and the synthesis of angiogenic factors, cell growth. Due to the location of abnormal blood vessels in the tumor tissue generated chaotic flow of blood, which leads to severe hypoxia - as a key factor in inducing the angiogenesis process. Hypoxia-inducible factor 1 (HIF-1) is the main molecule that regulates the growth and progression of glial tumors. Glioma cells, with their inherent properties of stem cells actively synthesized HIF-1. This population of cells called - “glioma stem cells” inducing synthesis of vascular endothelial growth factor (VEGF). It VEGF is central to the process of angiogenesis. A promising area of targeted therapy of brain gliomas is the anti-angiogenic therapy. Applications, both direct and indirect angiogenesis inhibitors, significantly improved the prognosis of patients with glial brain tumors. Undoubtedly an integrated approach to the study of microvascular disturbances, hypoxia, biology and cell behavior of “glioma stem cells” and the role of various factors of cell growth in the tumorigenesis of brain gliomas of the brain allows us to develop new and effective methods of diagnosis and treatment of this disease in the near future.

show abstract

Section: рецепторы Vegfunclassified

Molecular Aspects of Angiogenesis in Brain Glioblastomas

Byvaltsev¹,

Степанов²,

Belykh³

et al. 2017

Problems in oncology

View full text Add to dashboard Cite

show abstract

“…This model has allowed the study of some aspects related to tumour behaviour or possible treatment strategies in vivo [69]. …”

Section: An Experimental Model Of Endogenous Gliomamentioning

confidence: 99%

Angiogenic Signalling Pathways Altered in Gliomas: Selection Mechanisms for More Aggressive Neoplastic Subpopulations with Invasive Phenotype

Bulnes

Bengoetxea

Ortuzar

et al. 2012

Journal of Signal Transduction

View full text Add to dashboard Cite

The angiogenesis process is a key event for glioma survival, malignancy and growth. The start of angiogenesis is mediated by a cascade of intratumoural events: alteration of the microvasculature network; a hypoxic microenvironment; adaptation of neoplastic cells and synthesis of pro-angiogenic factors. Due to a chaotic blood flow, a consequence of an aberrant microvasculature, tissue hypoxia phenomena are induced. Hypoxia inducible factor 1 is a major regulator in glioma invasiveness and angiogenesis. Clones of neoplastic cells with stem cell characteristics are selected by HIF-1. These cells, called “glioma stem cells” induce the synthesis of vascular endothelial growth factor. This factor is a pivotal mediator of angiogenesis. To elucidate the role of these angiogenic mediators during glioma growth, we have used a rat endogenous glioma model. Gliomas induced by prenatal ENU administration allowed us to study angiogenic events from early to advanced tumour stages. Events such as microvascular aberrations, hypoxia, GSC selection and VEGF synthesis may be studied in depth. Our data showed that for the treatment of gliomas, developing anti-angiogenic therapies could be aimed at GSCs, HIF-1 or VEGF. The ENU-glioma model can be considered to be a useful option to check novel designs of these treatment strategies.

show abstract